Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25011 | 0.85 | GCK (0.60) | GCKRGCK | |
| SCHEMBL12089361 | 0.85 | GCKR (0.54) | GCKRGCK | |
| SCHEMBL12093339 | 0.84 | GCKR (0.69) | GCKRGCK | |
| SCHEMBL17638 | 0.84 | GCKR (0.69) | GCKRGCK | |
| SCHEMBL16985 | 0.84 | GCKR (0.72) | GCKRGCK | |
| SCHEMBL12078851 | 0.83 | GCKR (0.60) | GCKRGCK | |
| SCHEMBL33149 | 0.83 | GCKR (0.60) | GCKRGCK | |
| SCHEMBL15960 | 0.83 | GCKR (0.60) | GCKRGCK | |
| SCHEMBL33150 | 0.81 | GCKR (0.48) | GCKR | |
| Trifluoroacetic Acid SCHEMBL22286 | 0.80 | GCKR (0.64) | GCKRGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | claimed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |